Developing the leading the treatment for all forms of acute infectious conjunctivitis
We are exclusively focused on developing the leading treatment for acute infectious conjunctivitis (also known as pink eye).
Our lead product candidate, OKG-0303, is being developed to treat acute infectious conjunctivitis. It is a fixed dose eyedrop consisting of a proprietary antiviral, an ocular decongestant and an antibacterial.
© $year Okogen, Inc. All Rights Reserved
United States
Okogen, Inc.
8400 Belleview Drive, Suite 125
Plano, Texas 75024
USA
Australia
Okogen Pty Ltd
Level 9, 31 Queen St
Melbourne, VIC 3000
AUS
